AEON insider filings
AEON Biopharma, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-21. Screen AEON transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 1,150,000 shares, $243,455 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 1,150,000 shares @ $0.21 ($243,455) by LYNCH TIMOTHY P, filed 2026-08-21.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| LYNCH TIMOTHY P — 10% owner | 1 | 1 leg · 1,150,000 sh · $243,455 | — | — |
Recent insider filings — AEON Biopharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | LYNCH TIMOTHY P — 10% owner | Purchase (P): 1,150,000 @ $0.21 | EDGAR |
| 2026-06-22 | 4 | Forth Marc — Director | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-06-22 | 4 | Carter Eric G — Director | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-06-22 | 4 | FISCHER JOST — Director | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-06-22 | 4 | Thunen Shelley B — Director | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-06-22 | 4 | PALMISANO ROBERT J — Director | Grant/award (A): 222,684 @ $0 | EDGAR |
| 2026-04-03 | 4 | Bencich John — CHIEF FINANCIAL OFFICER | Grant/award (A): 754,717 @ $0 | EDGAR |
| 2026-03-11 | 4 | Oh Chad — CHIEF MEDICAL OFFICER | Grant/award (A): 862,500 @ $0 · Grant/award (A): 1,316,872 @ $0 | EDGAR |
| 2026-03-05 | 4 | Wilson Alexander Blair — CLO, CSO, and Corp Secretary | Grant/award (A): 862,500 @ $0 · Grant/award (A): 1,316,872 @ $0 | EDGAR |
| 2026-03-05 | 4 | Sy Jennifer — PRINCIPAL ACCOUNTING OFFICER | Grant/award (A): 575,000 @ $0 · Grant/award (A): 925,925 @ $0 | EDGAR |
| 2026-02-19 | 4 | Bancroft Robert E. — PRESIDENT & CEO, Director | Grant/award (A): 3,000,000 @ $0 | EDGAR |
| 2025-05-23 | 4 | Wilson Alexander Blair — Exec VP, CLO & Corp Secretary | Grant/award (A): 1,316,872 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Oh Chad — Chief Medical Officer | Grant/award (A): 1,316,872 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Sy Jennifer — Chief Accounting Officer | Grant/award (A): 925,925 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Forth Marc — Director | Grant/award (A): 370,370 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Carter Eric G — Director | Grant/award (A): 308,641 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | FISCHER JOST — Director | Grant/award (A): 308,641 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | FISCHER JOST — Director | Purchase (P): 60,000 @ $0.49 | EDGAR |
| 2025-05-23 | 4 | Thunen Shelley B — Director | Grant/award (A): 308,641 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | PALMISANO ROBERT J — Director | Grant/award (A): 308,641 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | FISCHER JOST — Director | Purchase (P): 50,000 @ $0.50 · Purchase (P): 60,000 @ $0.51 | EDGAR |
| 2025-05-16 | 4 | Bancroft Robert E. — President & CEO, Director | Grant/award (A): 177,103 @ $0 | EDGAR |
| 2025-05-01 | 4 | Bancroft Robert E. — President & CEO, Director | Grant/award (A): 59,034 (derivative) @ $0 | EDGAR |
| 2024-09-10 | 4/A | PALMISANO ROBERT J — Director | Grant/award (A): 36,021 @ $0 | EDGAR |
| 2024-09-04 | 4 | Wilson Alexander Blair — EXEC VP, CLO & CORP SECRETARY | Grant/award (A): 180,110 @ $0 · Grant/award (A): 480,631 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Oh Chad — CHIEF MEDICAL OFFICER | Grant/award (A): 192,117 @ $0 · Grant/award (A): 512,673 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Sy Jennifer — PRINCIPAL ACCOUNTING OFFICER | Grant/award (A): 18,010 @ $0 · Grant/award (A): 48,063 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Forth Marc — CHIEF EXECTUIVE OFFICER, Director | Grant/award (A): 470,692 @ $0 · Grant/award (A): 1,256,062 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Carter Eric G — Director | Grant/award (A): 36,021 @ $0 · Grant/award (A): 96,210 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | FISCHER JOST — Director | Grant/award (A): 36,021 @ $0 · Grant/award (A): 96,210 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Thunen Shelley B — Director | Grant/award (A): 36,021 @ $0 · Grant/award (A): 96,210 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | PALMISANO ROBERT J — Director | Grant/award (A): 36,021 @ $0 · Grant/award (A): 96,210 (derivative) @ $0 | EDGAR |
| 2024-04-16 | 4/A | Daewoong Co., Ltd — 10% owner | Other (J) | EDGAR |
| 2024-04-12 | 4 | Daewoong Co., Ltd — 10% owner | Other (J) | EDGAR |
| 2024-03-26 | 4 | Daewoong Co., Ltd — 10% owner | Other (J) | EDGAR |
| 2024-03-21 | 4 | Oh Chad — CHIEF MEDICAL OFFICER | Grant/award (A): 86,720 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | Wilson Alexander Blair — EXEC VP, CLO & CORP SECRETARY | Grant/award (A): 81,300 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | Forth Marc — CHIEF EXECTUIVE OFFICER, Director | Grant/award (A): 212,466 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | Carter Eric G — Director | Grant/award (A): 16,260 (derivative) @ $0 · Grant/award (A): 8,130 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | FISCHER JOST — Director | Grant/award (A): 16,260 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | Thunen Shelley B — Director | Grant/award (A): 16,260 (derivative) @ $0 | EDGAR |
| 2024-03-21 | 4 | PALMISANO ROBERT J — Director, 10% owner | Grant/award (A): 16,260 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | Carter Eric G — Director | Grant/award (A): 58,851 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | FISCHER JOST — Director | Grant/award (A): 58,851 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | Thunen Shelley B — Director | Grant/award (A): 58,851 (derivative) @ $0 | EDGAR |
| 2023-08-16 | 4 | PALMISANO ROBERT J — Director, 10% owner | Grant/award (A): 58,851 (derivative) @ $0 | EDGAR |
| 2023-08-14 | 4 | Strathspey Crown Holdings Group, LLC — 10% owner | Sale (S): 7,380,394 @ $10 | EDGAR |
| 2023-07-26 | 4 | Priveterra Sponsor, LLC — 10% owner Grodnensky Oleg — 10% owner PALMISANO ROBERT J — Director, 10% owner Malik Vikram — 10% owner | Conversion (C): 6,900,000 · Conversion (C): 89,163 · Conversion (C): 6,900,000 (derivative) · Grant/award (A): 5,280,000 (derivative) · Conversion (C): 38,824 (derivative) · Conversion (C): 38,824 (derivative) · +5 more | EDGAR |
| 2023-07-24 | 4 | Carter Eric G — Director | Grant/award (A): 9,007 (derivative) @ $0 · Grant/award (A): 11,802 (derivative) @ $0 | EDGAR |
| 2023-07-24 | 4 | FISCHER JOST — Director | Grant/award (A): 13,274 · Grant/award (A): 2,353 · Grant/award (A): 21,974 (derivative) @ $0 · Grant/award (A): 19,800 (derivative) @ $0 · Grant/award (A): 21,198 (derivative) @ $0 · Grant/award (A): 19,286 (derivative) @ $0 · +2 more | EDGAR |
Recent 8-K events — AEON Biopharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-30 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-03 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AEON returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →